{% trans 'Aller en haut'}
Logo antibiofilmogramme

Antibiofilmogram® | A BioFilm Control project

a new tool in the fight against bacterial infections

The antibiofilmogram® project

abstract illustration of antibiofilmogramme project

Project summary

The purpose of the BIOFILM project is to develop a new bacterial susceptibility test called Antibiofilmogram®. An antibiogram is the result of a laboratory testing for the sensitivity of an isolated bacterial strain to different antibiotics. The new Antibiofilmogram® test takes into account the biofilm behaviour of the microorganisms to potentially better prevent classical antibiotics treatment failures.

The BIOFILM project gives French companies of the clinical diagnostics market, especially BIOFILM CONTROL, the opportunity to take the leadership ahead of their competitors. The international recognised experience of each partner of the project in their own area of business and their critical size are significant assets to face the international competition.


Read more


The project in details

There is considerable pressure on hospital microbiology laboratories, which can receive and test more than 1,000 samples per day, to provide the best possible quality test results as quickly as possible, in particular given the rapid increase in multi-resistance bacteria, the growing list of super bugs responsible for potentially fatal infections and the reduction in the number of staff qualified in microbiology.

Given these facts, new technologies and automated solutions must be created to substantially reduce the needed time to provide clinicians with the following results:

  • What germ is responsible for the infection?
  • Which antibiotic, and dose, is most effective against this germ?

Microorganisms can follow one of two radically different life styles: planktonic and sessile. The former relates to a free bacteria population that inhabits a liquid environment, while the latter takes effect as soon as the bacterial community begins to attach itself to a solid support and secretes slimy substances to form a biofilm. Bacteria in biofilm form are more resistant to external attacks, particularly from biocides and antibiotics.

Demonstrating the clinical value of early detection of biofilm in response to contact with an antibiotic will give clinicians the information for which they have been yearning. They are particularly eager to find a way of determining the effectiveness of an antibiotic to inhibit the biofilm, which is a bacterial behaviour that increases risk to the patient. This is particularly an important factor, with regard to the risk of infection such as urinary infections in pregnant women, immunodeficient patients, patients in intensive care or fitted with medical devices of prostheses and so on. Aside from extreme cases, being able to give better-informed prescriptions enables clinicians to save time and cost (assessed $2,500 per patient per day) relating to hospitalisation or outpatient treatment.

An innovative project:

BIOFILM CONTROL provides a new, patented technological test - the BioFilm Ring Test® (BRT) – that will enable to assess the effectiveness of antibiotics to prevent or kill the microorganism organised in biofilm :

  • It gives new information that clinicians may use to verify the effectiveness of an antibiotic in inhibiting the installation of a biofilm, that increases the risk to patients;
  • It is a fast test that yields results within
  • It is a phenotypic test of resistant behaviour: the result will be correct even if a new mutation is responsible for a new type of resistance and this is a key advantage compared to genotypic tests;
  • The technology is compatible with existing platforms (bioMérieux, BD, Siemens, etc.);
  • It offers a big competitive advantage. Antibiofilmogram® will cause a power shift by disrupting the established order which has seen 3 leaders dominate for years with products that are quite similar and will move beyond the traditional diffusion techniques (known as Kirby-Bauer).

An opportunity in the current context:

In vitro diagnostics provide the tools, reagents and databases needed to examine information about the patient from samples of tissue and human bodily fluids. It forms an important link in the treatment chain, as 60-70% of medical decisions are taken from in vitro diagnostics results.

The annual global market in Microbiological Diagnostics accounts for 7% of the in vitro diagnostics market, which is worth some 30 billion euro. It has been growing by 4-5% per year.

60 à 70% décisions médicales
60-70% of medical decisions are taken from in vitro diagnostics results
Figure 2
The in vitro diagnostics market is worth 30 billion euro

Project impact

Clinical value

Improved medical service delivered without excessive cost overrun;

Improved medical service delivered with excessive cost overrun; optimised selection of antibiotics before administration

Social value

Social interest in hospital as city

In hospitals: reduced hospitalisation time (average cost $2,500 per day);
In the workplace: fewer absences of work due to illness

The BioFilm Ring Test® in action

A bacterial solution is dispensed in wells with particles that can be magnetised. When a magnet is put at the bottom of wells all particles will be attracted to form a central spot if no biofilm is present. As the biofilm is forming, the particles will be immobilised and the spot does not appear.

Analysis of the I0 (prior magnetization) and I1 (after magnetization) images with the BFC Elements software shows the biofilm forming index (BFI).


Antibiofilmogram® news

  • 5-7 October 2016
    23 September 2016

    5-7 October 2016

    BioFilm Control will participate and showcase its technology at the Antimicrobial resistance in microbial biofilms and options for treatment ...


    read more
  • 8-9 September 2016 BioFilm Control will attend as Platinum Sponsor the World Anti- microbial Resistance Congress US 2016 in Washington, USA
    22 August 2016

    8-9 September 2016 BioFilm Control will attend as Platinum Sponsor the World Anti- microbial Resistance Congress US 2016 in Washington, USA

    BioFilm Control organizes during the World Anti- microbial Resistance Congress a Biofilm session with the participation of Robin Patel ...


    read more
  • 2 publications from our Ph.D. students
    22 August 2016

    2 publications from our Ph.D. students

    - Elodie Olivares (Institute of Bacteriology, EA7290 Virulence bactérienne précoce, Strasbourg, France) : The BioFilm Ring Test: a Rapid ...


    read more
  • The poster presented by Elodie OLIVARES at the MEETING OF ESCMID STUDY GROUP FOR BIOFILMS (Roma, 9-10 octobre 2014) awarded
    17 October 2014

    The poster presented by Elodie OLIVARES at the MEETING OF ESCMID STUDY GROUP FOR BIOFILMS (Roma, 9-10 octobre 2014) awarded

    The poster presented by Elodie OLIVARES (co-directed thesis BioFilm Control / Institute of Bacteriology, Early Bacterial Virulence EA7290, Strasbourg, FRANCE ...


    read more
  • BioFilm Control will attend the next MEETING OF ESCMID STUDY GROUP FOR BIOFILMS (ESGB)
    23 September 2014

    BioFilm Control will attend the next MEETING OF ESCMID STUDY GROUP FOR BIOFILMS (ESGB)

    BioFilm Control will attend the next MEETING OF ESCMID STUDY GROUP FOR BIOFILMS (ESGB), Rome, the 9th and 10th ...


    read more

contact-us

Copyright © 2016 BioFilm Control. All right reserved.

Design : Askin